| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | 1,944 | 1,844 | 1,160 | 1,742 |
| Net loss | -12,585 | -20,340 | -25,120 | -23,420 |
| Unrealized gain (loss) on marketable securities and cash equivalents | 250 | -46 | -94 | 522 |
| Comprehensive loss | -12,335 | -20,386 | -25,214 | -22,898 |
| Net loss per share - basic (usd per share) | -0.3 | -0.48 | -0.64 | -0.61 |
| Net loss per share - diluted (usd per share) | -0.3 | -0.48 | -0.64 | -0.61 |
| Weighted-average shares outstanding - diluted (in shares) | 42,607,717 | 42,360,452 | 39,345,359 | 38,381,968 |
| Weighted-average shares outstanding, basic (in shares) | 42,607,717 | 42,360,452 | 39,345,359 | 38,381,968 |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)